A detailed history of Capital International Investors transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital International Investors holds 3,970,863 shares of ALNY stock, worth $972 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
3,970,863
Previous 3,891,059 2.05%
Holding current value
$972 Million
Previous $946 Million 15.52%
% of portfolio
0.22%
Previous 0.2%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$233.81 - $287.01 $18.7 Million - $22.9 Million
79,804 Added 2.05%
3,970,863 $1.09 Billion
Q2 2024

Aug 13, 2024

BUY
$143.31 - $247.0 $34.4 Million - $59.2 Million
239,842 Added 6.57%
3,891,059 $946 Million
Q1 2024

May 14, 2024

BUY
$146.51 - $198.2 $9.46 Million - $12.8 Million
64,560 Added 1.8%
3,651,217 $546 Million
Q4 2023

Feb 13, 2024

BUY
$151.41 - $196.57 $74 Million - $96.1 Million
488,814 Added 15.78%
3,586,657 $687 Million
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $37.1 Million - $46 Million
217,200 Added 7.54%
3,097,843 $549 Million
Q2 2023

Aug 11, 2023

BUY
$185.01 - $212.05 $120 Million - $138 Million
651,054 Added 29.2%
2,880,643 $547 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $40.9 Million - $52.8 Million
223,968 Added 11.17%
2,229,589 $447 Million
Q4 2022

Feb 14, 2023

BUY
$185.53 - $241.31 $10.9 Million - $14.2 Million
58,907 Added 3.03%
2,005,621 $477 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $43.3 Million - $72.5 Million
312,477 Added 19.12%
1,946,714 $390 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $197 Million - $277 Million
1,634,237 New
1,634,237 $238 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.